Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above

NCT ID: NCT07327398

Last Updated: 2026-01-15

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 1200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-07
• Study Completion Date: 2026-09-30

Brief Summary

To evaluate the immunogenicity of administering one dose of influenza virus split vaccine (0.7mL/dose) to individuals aged 60 and above.

Detailed Description

This is a randomized, blinded, parallel controlled trial design, a total of 1200 participants aged ≥ 60 years were enrolled in the study. Study participants were randomly vaccinated with either the experimental vaccine: influenza virus split vaccine (0.7mL/dose) or the control vaccine: influenza virus split vaccine, at a 1:1 ratio. One dose of the vaccine was administered on day 0 for immunogenicity and safety evaluation.

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Influenza virus split vaccine (0.7mL/vial)

Influenza virus split vaccine (0.7mL/vial)

Group Type: EXPERIMENTAL

Influenza virus split vaccine (0.7mL/vial)

Intervention Type: BIOLOGICAL

Influenza virus split vaccine, with a specification of 0.7mL/bottle, containing 60 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each Control: Influenza virus split vaccine.

Influenza virus split vaccine

Influenza virus split vaccine

Group Type: ACTIVE_COMPARATOR

Influenza virus split vaccine

Intervention Type: BIOLOGICAL

Influenza virus split vaccine, with a specification of 0.5mL/bottle, containing 15 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each.

Interventions

Influenza virus split vaccine (0.7mL/vial)

Influenza virus split vaccine, with a specification of 0.7mL/bottle, containing 60 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each Control: Influenza virus split vaccine.

Intervention Type: BIOLOGICAL

Influenza virus split vaccine

Influenza virus split vaccine, with a specification of 0.5mL/bottle, containing 15 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Age over 60 years old, gender not limited, and able to provide legal identification;
• Volunteers voluntarily participate in the study and sign an informed consent form;
• Volunteers have the ability to understand research procedures, use thermometers, scales, and fill out diary cards as required, and can participate in all planned follow-up visits.

Exclusion Criteria

• On the day of enrollment, the axillary temperature was ≥ 37.3 ℃;
• Those who have had influenza in the past 6 months or meet the definition of influenza like cases;
• Have received any influenza vaccine within the past 12 months or have planned to receive any influenza vaccine during the study period;
• Allergies to any components of the research vaccine, history of allergic reactions to the use of gentamicin sulfate, history of severe allergies to any vaccine/drug, or history of asthma;
• Suffering from a serious illness that prevents the completion of the entire study; Within 3 days prior to vaccination, there is an acute illness or an acute exacerbation of a chronic disease;
• Have used antipyretic or analgesic drugs or anti allergic drugs within 3 days before vaccination;
• Have received any vaccine within 2 weeks prior to vaccination;
• Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months prior to receiving the experimental vaccine, For example, immunosuppressive doses of glucocorticoids, monoclonal antibodies, thymosin, interferon, etc., or planned to receive such treatment within one month after the first dose of vaccination to full immunization, but local medication is allowed;
• Suffering from congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, or other autoimmune diseases;
• Suffering from serious chronic diseases, serious cardiovascular diseases, such as hypertension that cannot be controlled by drugs, diabetes that cannot be controlled by drugs or has serious complications, liver and kidney diseases, pulmonary edema, malignant tumors, etc;
• Have received blood or blood related products within the past 6 months;
• Individuals with progressive neurological disorders, including a history of seizures, epilepsy, encephalopathy, Guillain Barr é syndrome, psychiatric or family history;
• Have a history of abnormal coagulation function and have been using anticoagulants within 3 weeks before vaccination;
• Patients with splenectomy, functional splenectomy, splenectomy, or other important organ resection or partial resection;
• Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
• Currently or recently planning to participate in other clinical trials;
• Researchers determine any situation that is not suitable for clinical trials.

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Shanghai Institute Of Biological Products

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Danjiangkou City Center for Disease Control and Prevention

Wuhan, Hubei, China

Yunxi County Center for Disease Control and Prevention

Wuhan, Hubei, China

Countries

China

Central Contacts

Yang Liu

Role: CONTACT

liuyang30@sinopharm.com

86-010-65777702

Chaorong Xu

Role: CONTACT

xuchaorong@sinopharm.com

86-021-62800991

Facility Contacts

Yunbo Pan

Role: primary

2792320450@qq.com

86-15897801799

Ming Sang

Role: primary

386254647@qq.com

86-13597881368

Other Identifiers

SIBP-V05-002

Identifier Type: -

Identifier Source: org_study_id